Alcon (ALC) 6-K20 Aug 242024 Q2 Alcon Reports Second-Quarter 2024 Results with Strong Growth in Implantables and Contact LensesFinancial data

Company Profile

Cover

Cover	6 Months Ended
Cover	Jun. 30, 2024
Cover [Abstract]
Document Type	6-K
Entity File Number	001-31269
Entity Registrant Name	ALCON INC.
Entity Address, Address Line One	Rue Louis-d'Affry 6
Entity Address, Address Line Two	1701
Entity Address, City or Town	Fribourg
Entity Address, Country	CH
Document Period End Date	Jun. 30, 2024
Entity Central Index Key	0001167379
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2

Consolidated Income Statement (

Consolidated Income Statement (unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Profit or loss [abstract]
Net sales to third parties	$ 2,482	$ 2,402	$ 4,926	$ 4,735
Other revenues	14	20	29	39
Net sales and other revenues	2,496	2,422	4,955	4,774
Cost of net sales	(1,108)	(1,040)	(2,171)	(2,070)
Cost of other revenues	(14)	(19)	(28)	(36)
Gross profit	1,374	1,363	2,756	2,668
Selling, general & administration	(837)	(832)	(1,639)	(1,617)
Research & development	(220)	(217)	(419)	(419)
Other income	5	5	11	10
Other expense	(4)	(49)	(23)	(104)
Operating income	318	270	686	538
Interest expense	(50)	(48)	(95)	(95)
Other financial income & expense	12	(9)	24	(17)
Income before taxes	280	213	615	426
Taxes	(57)	(44)	(144)	(83)
Net income	$ 223	$ 169	$ 471	$ 343
Earnings per share
Basic (in dollars per share)	$ 0.45	$ 0.34	$ 0.95	$ 0.70
Diluted (in dollars per share)	$ 0.45	$ 0.34	$ 0.95	$ 0.69
Weighted average number of shares outstanding
Basic (in shares)	494.5	493.2	494.1	492.8
Diluted (in shares)	497	495.7	496.7	495.9

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income (unaudited) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statement of comprehensive income [abstract]
Net income		$ 223	$ 169	$ 471	$ 343
Other comprehensive income to be eventually recycled into the Consolidated Income Statement:
Currency translation effects, net of taxes	[1]	(22)	(18)	(74)	9
Total of items to eventually recycle		(22)	(18)	(74)	9
Other comprehensive income never to be recycled into the Consolidated Income Statement:
Actuarial gains/(losses) from defined benefit plans, net of taxes	[2]	5	1	19	(7)
Fair value adjustments on equity securities, net of taxes	[3]	4	1	5	2
Total of items never to be recycled		9	2	24	(5)
Total comprehensive income		$ 210	$ 153	$ 421	$ 347

[1] Amount is net of tax expense of $1 million for the three months ended June 30, 2024. Amount is net of tax benefit of $1 million for the three months ended June 30, 2023. Amount is net of tax expense of $0.5 million for the six months ended June 30, 2024. Amount is net of tax benefit of $1 million for the six months ended June 30, 2023. Amounts are net of tax expense of $2 million and $0.4 million for the three months ended June 30, 2024 and 2023, respectively. Amount is net of tax expense of $6 million for the six months ended June 30, 2024. Amount is net of tax benefit of $2 million for the six months ended June 30, 2023. Amounts are net of tax expense of $0.9 million and $0.4 million for the three months ended June 30, 2024 and 2023, respectively. Amounts are net of tax expense of $1 million and $0.8 million for the six months ended June 30, 2024 and 2023, respectively.

Consolidated Statement of Com_2

Consolidated Statement of Comprehensive Income (unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statement of comprehensive income [abstract]
Currency translation effects, tax (benefit) expense	$ 1	$ (1)	$ 0.5	$ (1)
Actuarial gains/(losses) from defined benefit plans, tax expense (benefit)	2	0.4	6	(2)
Fair value adjustments on equity securities, tax expense	$ 0.9	$ 0.4	$ 1	$ 0.8

Consolidated Balance Sheet (una

Consolidated Balance Sheet (unaudited) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Non-current assets
Property, plant & equipment	$ 4,330	$ 4,369
Right-of-use assets	356	354
Goodwill	8,926	8,926
Intangible assets other than goodwill	8,760	9,060
Deferred tax assets	448	443
Financial assets	608	517
Other non-current assets	303	298
Total non-current assets	23,731	23,967
Current assets
Inventories	2,332	2,322
Trade receivables	1,829	1,770
Income tax receivables	20	34
Cash and cash equivalents	1,372	1,094
Other current assets	434	427
Total current assets	5,987	5,647
Total assets	29,718	29,614
Equity
Share capital	20	20
Reserves	20,921	20,604
Total equity	20,941	20,624
Non-current liabilities
Financial debts	4,550	4,676
Lease liabilities	332	335
Deferred tax liabilities	792	797
Provisions & other non-current liabilities	763	784
Total non-current liabilities	6,437	6,592
Current liabilities
Trade payables	868	811
Financial debts	137	63
Lease liabilities	71	71
Current income tax liabilities	187	114
Provisions & other current liabilities	1,077	1,339
Total current liabilities	2,340	2,398
Total liabilities	8,777	8,990
Total equity and liabilities	$ 29,718	$ 29,614

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity (unaudited) - USD ($) $ in Millions		Total	Share capital	Other reserves	Fair value adjustments on equity investments	Actuarial gains from defined benefit plans	Cumulative currency translation effects	Total value adjustments	[1]
Beginning balance at Dec. 31, 2022		$ 19,677	$ 20	$ 19,673	$ (33)	$ 67	$ (50)	$ (16)
Net income		343		343
Other comprehensive income/(loss)		4			2	(7)	9	4
Total comprehensive income		347		343	2	(7)	9	4
Dividends		(117)		(117)
Equity-based compensation		23		23
Other movements	[2]	9		9
Total other movements		(85)		(85)
Ending balance at Jun. 30, 2023		19,939	20	19,931	(31)	60	(41)	(12)
Beginning balance at Dec. 31, 2023		20,624	20	20,624	(32)	37	(25)	(20)
Net income		471		471
Other comprehensive income/(loss)		(50)			5	19	(74)	(50)
Total comprehensive income		421		471	5	19	(74)	(50)
Dividends		(131)		(131)
Equity-based compensation		29		29
Other movements	[2]	(2)		(2)
Total other movements		(104)		(104)
Ending balance at Jun. 30, 2024		$ 20,941	$ 20	$ 20,991	$ (27)	$ 56	$ (99)	$ (70)

[1]"Total value adjustments" are presented net of the corresponding tax effects.[2] Activity includes hyperinflationary accounting.

Consolidated Statement of Cash

Consolidated Statement of Cash Flows (unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Statement of cash flows [abstract]
Net income	$ 471	$ 343
Adjustments to reconcile net income to net cash flows from operating activities
Depreciation, amortization, impairments and fair value adjustments	606	603
Equity-based compensation expense	77	74
Non-cash change in current and non-current provisions and other non-current liabilities	33	49
Losses on disposal and other adjustments on property, plant & equipment and other non-current assets, net	3	14
Interest expense	95	95
Other financial income & expense	(24)	17
Taxes	144	83
Interest received	31	15
Interest paid	(99)	(94)
Other financial payments	(5)	(4)
Taxes paid	(87)	(151)
Net cash flows before working capital changes and net payments out of provisions and other non-current liabilities	1,245	1,044
Net payments out of provisions and other cash movements in non-current liabilities	(58)	(214)
Change in net current assets and other operating cash flow items	(316)	(420)
Net cash flows from operating activities	871	410
Purchase of property, plant & equipment	(204)	(221)
Purchase of intangible assets	(59)	(132)
Payments for financial assets	(97)	(216)
Proceeds from financial assets	9	1
Net cash flows used in investing activities	(351)	(568)
Dividends paid to shareholders of Alcon Inc.	(130)	(116)
Repayment of current portion of non-current financial debts	(9)	(34)
Proceeds from current financial debts	39	40
Repayment of current financial debts	(38)	0
Proceeds from non-current financial debts, net of issuance costs	0	29
Other changes in financial debts	(7)	4
Lease payments	(43)	(38)
Payment of withholding taxes related to equity-based compensation	(42)	(43)
Other financing cash flows	(7)	(8)
Net cash flows used in financing activities	(237)	(166)
Effect of exchange rate changes on cash and cash equivalents	(5)	5
Net change in cash and cash equivalents	278	(319)
Cash and cash equivalents at January 1	1,094	980
Cash and cash equivalents at June 30	$ 1,372	$ 661

Selected accounting policies

Selected accounting policies	6 Months Ended
Selected accounting policies	Jun. 30, 2024
Corporate information and statement of IFRS compliance [abstract]
Selected accounting policies	Selected accounting policies Basis of preparation These Condensed Consolidated Interim Financial Statements for Alcon Inc. ("the Company") and the subsidiaries it controls (collectively, "Alcon") have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting, as issued by the International Accounting Standards Board ("IASB") and with the accounting policies as described in Note 2 to the December 31, 2023 Consolidated Financial Statements in the Company’s 2023 Form 20-F ("Form 20-F"). These Condensed Consolidated Interim Financial Statements do not include all of the information required for a complete set of International Financial Reporting Standards ("IFRS") financial statements. The financial information consolidates the Company and the subsidiaries it controls, and includes selected notes to explain events and transactions that are significant to an understanding of the changes in Alcon's financial position and performance since the prior annual Consolidated Financial Statements. Therefore, the Condensed Consolidated Interim Financial Statements should be read in conjunction with the annual Consolidated Financial Statements for the year ended December 31, 2023, which have been prepared in accordance with IFRS as issued by the IASB ("IFRS Accounting Standards") and can be found in the Form 20-F. The accompanying Condensed Consolidated Interim Financial Statements present our historical financial position, results of operations, comprehensive income and cash flows in accordance with IFRS Accounting Standards. Alcon's principal accounting policies are set out in Note 2 to the Consolidated Financial Statements in the Form 20-F. Use of estimates and assumptions The preparation of Condensed Consolidated Interim Financial Statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the period, that affect the reported amounts of assets and liabilities as well as revenues and expenses. Because of the inherent uncertainties, actual outcomes and results may differ from management's assumptions and estimates. Impairment of goodwill, Alcon brand name and definite lived intangible assets As discussed in Note 2 to the Consolidated Financial Statements in the Form 20-F, Goodwill, the Alcon brand name and acquired in-process research & development ("IPR&D") projects are reviewed for impairment at least annually and these, as well as all other investments in intangible assets, are reviewed for impairment whenever events or changes in circumstance indicate that the asset's balance sheet or reportable segment carrying amount may not be recoverable. Goodwill and other intangible assets represent a significant amount of total assets on the Consolidated Balance Sheet. Impairment testing may lead to potentially significant impairment charges in the future, which could have a materially adverse impact on Alcon's results of operations and financial condition. Impact of adopting Amendments to International Accounting Standards 1 Effective January 1, 2024, Alcon adopted Amendments to International Accounting Standards 1 ("IAS 1"), Presentation of Financial Statements, which clarified the criteria used in determining the classification on the balance sheet of a liability as non-current where an entity has the right to postpone settlement of the liability for at least twelve months after the reporting date. Upon adoption of the amendment, current financial debts of $82 million for which Alcon has a right to roll over for at least twelve months after the December 31, 2023 balance sheet date were retrospectively reclassified to non-current financial debts. New standards, interpretations and amendments not yet adopted In April 2024, the IASB issued IFRS 18, Presentation and Disclosure in Financial Statements, which will replace IAS 1, Presentation of Financial Statements and accompanies limited amendments to other standards which will be effective upon the adoption of the new standard. IFRS 18 will be retroactively effective for our annual reporting periods beginning on January 1, 2027, with early adoption permitted. The standard is expected to improve comparability and transparency of financial statements by requiring defined subtotals in the Consolidated Income Statement, requiring disclosure of management-defined performance measures and adding new principles for aggregation and disaggregation of information. Alcon is currently evaluating the impact of this standard on its Consolidated Financial Statements.

Segmentation of key figures

Segmentation of key figures	6 Months Ended
Segmentation of key figures	Jun. 30, 2024
Operating Segments [Abstract]
Segmentation of key figures	Segmentation of key figures The segment information disclosed in these Condensed Consolidated Interim Financial Statements reflects historical results consistent with the identifiable reportable segments of Alcon and financial information that the Chief Operating Decision Maker ("CODM") reviews to evaluate segmental performance and allocate resources among the segments. The CODM is the Executive Committee of Alcon. The businesses of Alcon are divided operationally on a worldwide basis into two identified reportable segments, Surgical and Vision Care. Alcon's reportable segments are the same as its operating segments as Alcon does not aggregate any operating segments in arriving at its reportable segments. As indicated below, certain income and expenses are not allocated to segments. Reportable segments are presented in a manner consistent with the internal reporting to the CODM. The reportable segments are managed separately due to their distinct needs and activities for research, development, manufacturing, distribution and commercial execution. The Executive Committee of Alcon is responsible for allocating resources and assessing the performance of the reportable segments. In Surgical, Alcon researches, develops, manufactures, distributes and sells ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio also includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end procedure needs of the ophthalmic surgeon. In Vision Care, Alcon researches, develops, manufactures, distributes and sells daily disposable, reusable, and color-enhancing contact lenses and a comprehensive portfolio of ocular health products, including products for dry eye, glaucoma, contact lens care and ocular allergies, as well as ocular vitamins and redness relievers. Alcon also provides services, training, education and technical support for both the Surgical and Vision Care businesses. The basis of preparation and the selected accounting policies mentioned in Note 1 are used in the reporting of segment results. The Executive Committee of Alcon evaluates segmental performance and allocates resources among the segments primarily based on net sales and segment contribution. Net identifiable assets are not assigned to the segments in the internal reporting to the CODM, and are not considered in evaluating the performance of the business segments by the Executive Committee of Alcon. Segment contribution excludes amortization and impairment charges for acquired product rights or other intangibles, general and administrative expenses for corporate activities, transformation costs, fair value adjustments to contingent consideration liabilities, past service costs primarily for post-employment benefit plan amendments, acquisition and integration related costs, certain acquisition related items and certain other income and expense items. General & administration (corporate) includes the costs of the Alcon corporate headquarters, including all related corporate function costs. Other income and expense items excluded from segment contribution include fair value adjustments of financial assets in the form of options to acquire a company carried at fair value through profit and loss ("FVPL"), net gains and losses on fund investments and equity securities valued at FVPL, restructuring costs, legal provisions and settlements and other income and expense items not attributed to a specific segment. Net sales and other revenues by segment Three months ended June 30 Six months ended June 30 ($ millions) 2024 2023 2024 2023 Surgical Implantables 464 437 897 864 Consumables 736 714 1,422 1,370 Equipment/other 223 231 442 452 Total Surgical net sales to third parties 1,423 1,382 2,761 2,686 Vision Care Contact lenses 636 594 1,307 1,209 Ocular health 423 426 858 840 Total Vision Care net sales to third parties 1,059 1,020 2,165 2,049 Total net sales to third parties 2,482 2,402 4,926 4,735 Vision Care other revenues 14 20 29 39 Total net sales and other revenues 2,496 2,422 4,955 4,774 Segment contribution and reconciliation to income before taxes Three months ended June 30 Six months ended June 30 ($ millions) 2024 2023 2024 2023 Segment contribution Surgical 403 407 789 788 Vision Care 180 174 438 373 Total segment contribution 583 581 1,227 1,161 Not allocated to segments: Amortization of intangible assets (184) (187) (367) (377) Impairment charges on intangible assets (9) — (9) — General & administration (corporate) (73) (74) (148) (142) Transformation costs — (26) — (52) Integration related costs — (8) — (14) Other 1 (16) (17) (38) Operating income 318 270 686 538 Interest expense (50) (48) (95) (95) Other financial income & expense 12 (9) 24 (17) Income before taxes 280 213 615 426 Net sales by region (1) Three months ended June 30 Six months ended June 30 ($ millions unless indicated otherwise) 2024 2023 2024 2023 United States 1,141 46 % 1,105 46 % 2,290 46 % 2,183 46 % International 1,341 54 % 1,297 54 % 2,636 54 % 2,552 54 % Net sales to third parties 2,482 100 % 2,402 100 % 4,926 100 % 4,735 100 % (1) Net sales to third parties by location of third-party customer.

Dividends and earnings per shar

Dividends and earnings per share	6 Months Ended
Dividends and earnings per share	Jun. 30, 2024
Earnings per share [abstract]
Dividends and earnings per share	Dividends and earnings per share Dividends On February 27, 2024, the Company's Board of Directors (the "Board") proposed a dividend of CHF 0.24 per share, which was subsequently approved by the shareholders at the Annual General Meeting on May 8, 2024 and paid in May 2024 for an amount of $130 million. On February 27, 2023, the Board proposed a dividend of CHF 0.21 per share, which was subsequently approved by the shareholders at the Annual General Meeting on May 5, 2023 and paid in May 2023 for an amount of $116 million. Earnings per share As of June 30, 2024, there were 494.5 million outstanding common shares, after the delivery of 1.2 million net shares vesting under the equity incentive programs during the six months ended June 30, 2024. Basic earnings per share is computed by dividing net income for the period by the weighted average number of common shares outstanding during the period. For the three and six months ended June 30, 2024, the weighted average number of shares outstanding was 494.5 million and 494.1 million, respectively. For the three and six months ended June 30, 2023, the weighted average number of shares outstanding was 493.2 million and 492.8 million, respectively. The only potentially dilutive securities are the outstanding unvested equity-based awards, as described in Note 8. Except when the effect would be anti-dilutive, the calculation of diluted earnings per common share includes the weighted average net impact of unvested equity-based awards. For the three and six months ended June 30, 2024, the weighted average diluted number of shares outstanding was 497.0 million and 496.7 million, respectively, which includes the potential conversion of 2.5 million and 2.6 million unvested equity-based awards, respectively. For the three and six months ended June 30, 2023, the weighted average diluted number of shares outstanding was 495.7 million and 495.9 million, respectively, which includes the potential conversion of 2.5 million and 3.1 million unvested equity-based awards, respectively.

Intangible assets other than go

Intangible assets other than goodwill	6 Months Ended
Intangible assets other than goodwill	Jun. 30, 2024
Disclosure of detailed information about intangible assets [abstract]
Intangible assets other than goodwill	Intangible assets other than goodwill Intangible asset impairment charges Impairment charges during the three and six months ended June 30, 2024 amounted to $9 million recognized in Research & development in the Condensed Consolidated Income Statement due to the full impairment of an acquired IPR&D cash generating unit in the Surgical

Non-current and current financi

Non-current and current financial debts	6 Months Ended
Non-current and current financial debts	Jun. 30, 2024
Disclosure Of Borrowings [Abstract]
Non-current and current financial debts	Non-current and current financial debts The below table summarizes non-current and current Financial debts outstanding as of June 30, 2024 and December 31, 2023. ($ millions) June 30, 2024 December 31, 2023 Non-current financial debts Local facilities (Japan), floating rate debt due 2025 (1) — 110 2.750% Series 2026 Notes 498 498 2.375% Series 2028 Notes 531 549 3.000% Series 2029 Notes 995 994 2.600% Series 2030 Notes 746 746 5.375% Series 2032 Notes 693 693 3.800% Series 2049 Notes 495 494 5.750% Series 2052 Notes 592 592 Revolving facility, floating rate due 2028 — — Total non-current financial debts 4,550 4,676 Current financial debts Local facilities, floating rate: Japan (1) 74 — All others 50 48 Other short-term financial debts, floating rate 12 5 Derivatives 1 10 Total current financial debts 137 63 Total financial debts 4,687 4,739 (1) As described in Note 1, Alcon adopted Amendments to IAS 1, Presentation of Financial Statements, effective January 1, 2024, resulting in retrospective reclassification of certain financial debts from current to non-current. Interest expense recognized for Financial debts, excluding lease liabilities, was $43 million and $83 million for the three and six months ended June 30, 2024, respectively, and $40 million and $81 million for the three and six months ended June 30, 2023, respectively. Revolving credit facility

Financial instruments

Financial instruments	6 Months Ended
Financial instruments	Jun. 30, 2024
Financial Instruments [Abstract]
Financial instruments	Financial instruments Fair value by hierarchy As required by IFRS, financial assets and liabilities recorded at fair value in the Condensed Consolidated Interim Financial Statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. There are three hierarchical levels, based on an increasing amount of judgment associated with the inputs to derive fair value for these financial assets and liabilities, which are as follows: Financial assets and liabilities carried at Level 1 fair value hierarchy are listed in active markets. Financial assets and liabilities carried at Level 2 fair value hierarchy are valued using corroborated market data. Level 1 financial assets include money market funds and deferred compensation assets. There were no financial liabilities carried at Level 1 fair value, and Level 2 financial assets and liabilities include derivative financial instruments. Investments in money market funds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The investments are classified as Cash & cash equivalents within the Condensed Consolidated Balance Sheet. Deferred compensation investments for certain employee benefit plans are held in a rabbi trust and dedicated to pay the benefits under the associated plans but are not considered plan assets as the assets remain available to creditors of Alcon in certain events, including bankruptcy. Rabbi trust assets primarily consist of investments in mutual funds. These assets are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. Level 3 inputs are unobservable for the financial asset or liability. The financial assets and liabilities generally included in the Level 3 fair value hierarchy are equity securities and convertible notes receivable of private companies measured at fair value through other comprehensive income ("FVOCI"), fund investments, options to acquire private companies, and contingent consideration liabilities measured at FVPL. The below tables summarize financial assets and liabilities measured at fair value on a recurring basis or at amortized cost or cost as of June 30, 2024 and December 31, 2023. June 30, 2024 ($ millions) Level 1 Level 2 Level 3 Valued at amortized cost or cost (4) Total Non-current financial assets Long-term financial investments measured at FVOCI (1) — — 243 — 243 Long-term financial investments measured at FVPL — — 1 — 1 Long-term note receivable and other financial assets measured at amortized cost — — — 168 168 Long-term receivables from customers — — — 118 118 Deferred compensation assets (2) 172 — — — 172 Non-current minimum lease payments from finance lease agreements — — — 35 35 Long-term loans, VAT receivables, advances and security deposits — — — 43 43 Non-current financial assets 172 — 244 364 780 Current financial assets Money market funds 237 — — — 237 Current portion of long-term financial investments measured at FVPL (3) — — 2 — 2 Current portion of long-term receivables from customers (3) — — — 115 115 Current portion of minimum lease payments from finance lease agreements (3) — — — 27 27 VAT receivables (3) — — — 61 61 Other receivables, security deposits and current assets (3) — — — 98 98 Derivative financial instruments (3) — 11 — — 11 Current financial assets 237 11 2 301 551 Financial assets at fair value and amortized cost or cost 409 11 246 665 1,331 Financial liabilities Contingent consideration liabilities — — (94) — (94) Non-current financial debt — — — (4,550) (4,550) Current financial debt — — — (136) (136) Derivative financial instruments — (1) — — (1) Financial liabilities at fair value and amortized cost — (1) (94) (4,686) (4,781) (1) Includes $11 million of Long-term convertible notes due from an associated company. (2) Recorded in Other non-current assets. (3) Recorded in Other current assets. (4) The carrying amount is a reasonable approximation of fair value, with the exception of the Series 2026, 2028, 2029, 2030, 2032, 2049 and 2052 Notes recorded in Non-current financial debt with a fair value of $4,232 million and a carrying value of $4,550 million as of June 30, 2024. The fair value of notes was determined using Level 2 inputs. The notes were valued using the quoted market price for such notes, which have low trading volumes. December 31, 2023 ($ millions) Level 1 Level 2 Level 3 Valued at amortized cost or cost (4) Total Non-current financial assets Long-term financial investments measured at FVOCI (1) — — 147 — 147 Long-term financial investments measured at FVPL — — 1 — 1 Long-term note receivable and other financial assets measured at amortized cost — — — 161 161 Long-term receivables from customers — — — 126 126 Deferred compensation assets (2) 163 — — — 163 Non-current minimum lease payments from finance lease agreements — — — 38 38 Long-term loans, VAT receivables, advances and security deposits — — — 44 44 Non-current financial assets 163 — 148 369 680 Current financial assets Money market funds 84 — — — 84 Current portion of long-term financial investments measured at FVPL (3) — — 7 — 7 Current portion of long-term receivables from customers (3) — — — 116 116 Current portion of minimum lease payments from finance lease agreements (3) — — — 27 27 VAT receivables (3) — — — 62 62 Other receivables, security deposits and current assets (3) — — — 101 101 Derivative financial instruments (3) — 2 — — 2 Current financial assets 84 2 7 306 399 Financial assets at fair value and amortized cost or cost 247 2 155 675 1,079 Financial liabilities Contingent consideration liabilities — — (90) — (90) Non-current financial debt — — — (4,676) (4,676) Current financial debt — — — (53) (53) Derivative financial instruments — (10) — — (10) Financial liabilities at fair value and amortized cost — (10) (90) (4,729) (4,829) (1) Includes $11 million of Long-term convertible notes due from an associated company. (2) Recorded in Other non-current assets. (3) Recorded in Other current assets. (4) The carrying amount is a reasonable approximation of fair value, with the exception of the Series 2026, 2028, 2029, 2030, 2032, 2049 and 2052 Notes recorded in Non-current financial debt with a fair value of $4,347 million and a carrying value of $4,566 million as of December 31, 2023. The fair value of notes was determined using Level 2 inputs. The notes were valued using the quoted market price for such notes, which have low trading volumes. The carrying amount is a reasonable approximation of fair value for all other financial assets and liabilities as of June 30, 2024, including Cash & cash equivalents, Trade receivables, Income tax receivables and Trade payables. There were no transfers of financial instruments between levels in the fair value hierarchy during the six months ended June 30, 2024. Level 3 financial instruments measured at fair value on a recurring basis Financial assets Long-term financial investments measured Financial investments ($ millions) 2024 2023 2024 2023 Balance as of January 1 147 88 8 20 Additions 90 53 — 8 Gains recognized in Consolidated Statement of Comprehensive Income 6 2 — — Gains/(losses) in Consolidated Income Statement — — 2 (4) Amortization — — (2) (1) Settlement — — (5) — Balance as of June 30 243 143 3 23 Financial liabilities Contingent consideration liabilities ($ millions) 2024 2023 Balance as of January 1 (90) (98) Accretion for passage of time (4) (4) Balance as of June 30 (94) (102) As of June 30, 2024, the probability of success for various development and commercial milestones ranges from 3% to 55% and the maximum remaining potential payments related to contingent consideration from business combinations is $395 million, plus other amounts calculated as a percentage of commercial sales in cases where there is not a specified maximum contractual payment amount. The estimation of probability typically depends on factors such as technical milestones or market performance and is adjusted for the probability of payment. If material, probable payments are appropriately discounted to reflect the impact of time. Contingent consideration liabilities are reported in “Provisions & other non-current liabilities" based on the projected timing of settlement which is estimated to range from 2029 through 2035 for contingent consideration obligations as of June 30, 2024. Long-term note receivable and other financial assets measured at amortized cost As described in Note 17 to the Consolidated Financial Statements in the Form 20-F, on May 22, 2023, Alcon entered into financing arrangements with a long-term supplier, Lifecore Biomedical, Inc. and certain of its affiliates (collectively, “Lifecore”) resulting in financial assets which Alcon concluded were originated credit-impaired. The maximum exposure to credit risk is reflected in the carrying value of the assets, which amounted to $169 million as of June 30, 2024, including a non-current portion of $168 million in "Long-term note receivable and other financial assets measured at amortized cost" in Financial assets and a current portion of $1 million in "Other receivables, security deposits and current assets" in Other current assets. As of June 30, 2024, in accordance with the terms of the Pledge and Security agreement (“security agreement”), the credit risk exposure is fully mitigated by the collateral, with an estimated amount of approximately $320 million. The estimated amount of collateral decreased approximately 15% from December 31, 2023 based on updated forecasts reflecting recent market data and discounted cash flow analysis. There have been no significant changes in the quality of the collateral, the terms of the signed security agreement or the credit monitoring procedures described in Note 17 to the Consolidated Financial Statements in the Form 20-F. In addition, as of June 30, 2024, Alcon assessed there was no lifetime expected credit loss due to the value of the collateral under the security agreement. Derivatives The below table summarizes the net value of unsettled positions for currency derivatives contracts including swaps, forwards and options as of June 30, 2024 and December 31, 2023. ($ millions) June 30, 2024 December 31, 2023 Unrealized gains in Other current assets 11 2 Unrealized losses in Current financial debts (1) (10) Net value of unsettled positions for derivatives contracts 10 (8) There are master agreements with several banking counterparties for derivative financial instruments; however, there were no derivative financial instruments meeting the offsetting criteria under IFRS as of June 30, 2024 or December 31, 2023. Nature and extent of risks arising from financial instruments Note 17 to the Consolidated Financial Statements in the Form 20-F contains a summary of the nature and extent of risks arising from financial instruments. There have been no significant updates to our assessment of the nature and extent of risks arising from financial instruments or corresponding risk management policies during the period.

Condensed Consolidated Statemen

Condensed Consolidated Statements of Cash Flows - additional details	6 Months Ended
	Jun. 30, 2024
Cash Flow Statement [Abstract]
Condensed Consolidated Statements of Cash Flows - additional details	Condensed Consolidated Statement of Cash Flows - additional details The below tables provide additional detail supporting select line items in the Condensed Consolidated Statement of Cash Flows. 7.1 Depreciation, amortization, impairments and fair value adjustments Six months ended June 30 ($ millions) 2024 2023 Property, plant & equipment 191 182 Right-of-use assets 40 40 Intangible assets 376 377 Financial assets — 5 Other non-current assets (1) (1) Total 606 603 7.2 Change in net current assets and other operating cash flow items Six months ended June 30 ($ millions) 2024 2023 (Increase) in inventories (71) (198) (Increase) in trade receivables (116) (138) Increase in trade payables 72 36 Net change in other operating assets (3) (44) Net change in other operating liabilities (198) (76) Total (316) (420)

Equity-based compensation

Equity-based compensation	6 Months Ended
Equity-based compensation	Jun. 30, 2024
Share-Based Payment Arrangements [Abstract]
Equity-based compensation	Equity-based compensation As described in Note 23 to the Consolidated Financial Statements in the Form 20-F, Alcon has various equity incentive plans, under which Alcon may grant awards in the form of restricted stock units ("RSUs"), performance-based restricted stock units ("PSUs"), restricted stock awards ("RSAs"), or any other form of award at the discretion of the Board. Certain associates in select countries may also participate in share ownership savings plans. The below table summarizes unvested share movements for all Alcon equity-based incentive plans for the six months ended June 30, 2024 and 2023: Six months ended June 30 (shares in millions) 2024 2023 Unvested at January 1 4.9 4.8 Granted 2.2 2.2 Vested (1.7) (1.8) Forfeited (0.1) (0.1) Unvested at June 30 5.3 5.1

Legal proceedings update

Legal proceedings update	6 Months Ended
Legal proceedings update	Jun. 30, 2024
Other Provisions, Contingent Liabilities And Contingent Assets [Abstract]
Legal proceedings update	Legal proceedings update A number of Alcon companies are, and will likely continue to be, subject to various legal proceedings and investigations that arise from time to time, including proceedings regarding product liability, sales and marketing practices, commercial disputes, employment, wrongful discharge, antitrust, securities, health and safety, environmental, tax, international trade, privacy, intellectual property, including under the Hatch-Waxman Act, and anti-bribery matters such as those under the Foreign Corrupt Practices Act of 1977 ("FCPA"), as amended. As a result, Alcon may become subject to substantial liabilities that may not be covered by insurance and could affect Alcon's business, financial position and reputation. While Alcon does not believe that any of these legal proceedings will have a material adverse effect on its financial position, litigation is inherently unpredictable and large judgments sometimes occur. As a consequence, Alcon may in the future incur judgments or enter into settlements of claims that could have a material adverse effect on its results of operations or cash flow. Note 18 to the Consolidated Financial Statements in the Form 20-F contains a summary of significant legal proceedings to which Alcon or any of its subsidiaries was a party as of the date of the Form 20-F. As of August 20, 2024, Alcon has fully and finally resolved the patent infringement claims it brought against the remaining defendants in the Hatch-Waxman litigation concerning Rocklatan and Rhopressa . There have been no other significant developments in the proceedings described in the Form 20-F nor any new significant proceedings commenced since the date of the Form 20-F. Alcon believes that its total provisions for litigation and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, additional liabilities and costs may be incurred beyond the amounts provided.

Related parties transactions

Related parties transactions	6 Months Ended
Related parties transactions	Jun. 30, 2024
Related Party [Abstract]
Related parties transactions	Related parties transactions Investment in an associated company As described in Note 24 to the Consolidated Financial Statements in the Form 20-F, Alcon holds approximately 8.5% voting interest of an associated company. The carrying amount of the investment in the associated company was $10 million as of June 30, 2024 and December 31, 2023. Long-term convertible notes due from the associated company included in Financial assets on the Condensed Consolidated Balance Sheet amounted to $11 million

Subsequent events

Subsequent events	6 Months Ended
Subsequent events	Jun. 30, 2024
Events After Reporting Period [Abstract]
Subsequent events	Subsequent events On August 12, 2024, Alcon entered into a set of definitive agreements with Ocumension Therapeutics (Hong Kong) Limited (“Ocumension”), subject to customary closing conditions. Under the terms of the agreements, Alcon will divest its rights in China in favor of Ocumension to Bion Tears and Tears Naturale (reported in Vision Care segment) and procedural eye drops (reported in Surgical segment). Ocumension will also license the exclusive commercialization rights to Systane Ultra in China and development and commercialization rights to AR-15512 in China. In exchange, Alcon will receive up-front consideration in the form of approximately 16.7% of the ordinary shares of Ocumension. Alcon will also receive royalties and defined AR-15512 sales milestones. The transaction is expected to close in the fourth quarter of 2024.

Selected accounting policies (P

Selected accounting policies (Policies)	6 Months Ended
Selected accounting policies (Policies)	Jun. 30, 2024
Corporate information and statement of IFRS compliance [abstract]
Statement of IFRS compliance	The accompanying Condensed Consolidated Interim Financial Statements present our historical financial position, results of operations, comprehensive income and cash flows in accordance with IFRS Accounting Standards.
Use of estimates and assumptions	Use of estimates and assumptions The preparation of Condensed Consolidated Interim Financial Statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the period, that affect the reported amounts of assets and liabilities as well as revenues and expenses. Because of the inherent uncertainties, actual outcomes and results may differ from management's assumptions and estimates.
Impairment of goodwill, Alcon brand name and definite lived intangible assets	Impairment of goodwill, Alcon brand name and definite lived intangible assets As discussed in Note 2 to the Consolidated Financial Statements in the Form 20-F, Goodwill, the Alcon brand name and acquired in-process research & development ("IPR&D") projects are reviewed for impairment at least annually and these, as well as all other investments in intangible assets, are reviewed for impairment whenever events or changes in circumstance indicate that the asset's balance sheet or reportable segment carrying amount may not be recoverable. Goodwill and other intangible assets represent a significant amount of total assets on the Consolidated Balance Sheet. Impairment testing may lead to potentially significant impairment charges in the future, which could have a materially adverse impact on Alcon's results of operations and financial condition.
Impact of adopting Amendments to International Accounting Standards 1	Impact of adopting Amendments to International Accounting Standards 1 Effective January 1, 2024, Alcon adopted Amendments to International Accounting Standards 1 ("IAS 1"), Presentation of Financial Statements, which clarified the criteria used in determining the classification on the balance sheet of a liability as non-current where an entity has the right to postpone settlement of the liability for at least twelve months after the reporting date. Upon adoption of the amendment, current financial debts of $82 million for which Alcon has a right to roll over for at least twelve months after the December 31, 2023
New standards, interpretations and amendments not yet adopted	New standards, interpretations and amendments not yet adopted In April 2024, the IASB issued IFRS 18, Presentation and Disclosure in Financial Statements, which will replace IAS 1, Presentation of Financial Statements and accompanies limited amendments to other standards which will be effective upon the adoption of the new standard. IFRS 18 will be retroactively effective for our annual reporting periods beginning on January 1, 2027, with early adoption permitted. The standard is expected to improve comparability and transparency of financial statements by requiring defined subtotals in the Consolidated Income Statement, requiring disclosure of management-defined performance measures and adding new principles for aggregation and disaggregation of information. Alcon is currently evaluating the impact of this standard on its Consolidated Financial Statements.

Segmentation of key figures (Ta

Segmentation of key figures (Tables)	6 Months Ended
Segmentation of key figures (Tables)	Jun. 30, 2024
Operating Segments [Abstract]
Disclosure of operating segments	Net sales and other revenues by segment Three months ended June 30 Six months ended June 30 ($ millions) 2024 2023 2024 2023 Surgical Implantables 464 437 897 864 Consumables 736 714 1,422 1,370 Equipment/other 223 231 442 452 Total Surgical net sales to third parties 1,423 1,382 2,761 2,686 Vision Care Contact lenses 636 594 1,307 1,209 Ocular health 423 426 858 840 Total Vision Care net sales to third parties 1,059 1,020 2,165 2,049 Total net sales to third parties 2,482 2,402 4,926 4,735 Vision Care other revenues 14 20 29 39 Total net sales and other revenues 2,496 2,422 4,955 4,774 Segment contribution and reconciliation to income before taxes Three months ended June 30 Six months ended June 30 ($ millions) 2024 2023 2024 2023 Segment contribution Surgical 403 407 789 788 Vision Care 180 174 438 373 Total segment contribution 583 581 1,227 1,161 Not allocated to segments: Amortization of intangible assets (184) (187) (367) (377) Impairment charges on intangible assets (9) — (9) — General & administration (corporate) (73) (74) (148) (142) Transformation costs — (26) — (52) Integration related costs — (8) — (14) Other 1 (16) (17) (38) Operating income 318 270 686 538 Interest expense (50) (48) (95) (95) Other financial income & expense 12 (9) 24 (17) Income before taxes 280 213 615 426
Disclosure of geographical areas	Net sales by region (1) Three months ended June 30 Six months ended June 30 ($ millions unless indicated otherwise) 2024 2023 2024 2023 United States 1,141 46 % 1,105 46 % 2,290 46 % 2,183 46 % International 1,341 54 % 1,297 54 % 2,636 54 % 2,552 54 % Net sales to third parties 2,482 100 % 2,402 100 % 4,926 100 % 4,735 100 % (1) Net sales to third parties by location of third-party customer.

Non-current and current finan_2

Non-current and current financial debts (Tables)	6 Months Ended
Non-current and current financial debts (Tables)	Jun. 30, 2024
Disclosure Of Borrowings [Abstract]
Schedule of financial debts	The below table summarizes non-current and current Financial debts outstanding as of June 30, 2024 and December 31, 2023. ($ millions) June 30, 2024 December 31, 2023 Non-current financial debts Local facilities (Japan), floating rate debt due 2025 (1) — 110 2.750% Series 2026 Notes 498 498 2.375% Series 2028 Notes 531 549 3.000% Series 2029 Notes 995 994 2.600% Series 2030 Notes 746 746 5.375% Series 2032 Notes 693 693 3.800% Series 2049 Notes 495 494 5.750% Series 2052 Notes 592 592 Revolving facility, floating rate due 2028 — — Total non-current financial debts 4,550 4,676 Current financial debts Local facilities, floating rate: Japan (1) 74 — All others 50 48 Other short-term financial debts, floating rate 12 5 Derivatives 1 10 Total current financial debts 137 63 Total financial debts 4,687 4,739

Financial instruments (Tables)

Financial instruments (Tables)	6 Months Ended
Financial instruments (Tables)	Jun. 30, 2024
Financial Instruments [Abstract]
Disclosure of fair value measurement of assets	The below tables summarize financial assets and liabilities measured at fair value on a recurring basis or at amortized cost or cost as of June 30, 2024 and December 31, 2023. June 30, 2024 ($ millions) Level 1 Level 2 Level 3 Valued at amortized cost or cost (4) Total Non-current financial assets Long-term financial investments measured at FVOCI (1) — — 243 — 243 Long-term financial investments measured at FVPL — — 1 — 1 Long-term note receivable and other financial assets measured at amortized cost — — — 168 168 Long-term receivables from customers — — — 118 118 Deferred compensation assets (2) 172 — — — 172 Non-current minimum lease payments from finance lease agreements — — — 35 35 Long-term loans, VAT receivables, advances and security deposits — — — 43 43 Non-current financial assets 172 — 244 364 780 Current financial assets Money market funds 237 — — — 237 Current portion of long-term financial investments measured at FVPL (3) — — 2 — 2 Current portion of long-term receivables from customers (3) — — — 115 115 Current portion of minimum lease payments from finance lease agreements (3) — — — 27 27 VAT receivables (3) — — — 61 61 Other receivables, security deposits and current assets (3) — — — 98 98 Derivative financial instruments (3) — 11 — — 11 Current financial assets 237 11 2 301 551 Financial assets at fair value and amortized cost or cost 409 11 246 665 1,331 Financial liabilities Contingent consideration liabilities — — (94) — (94) Non-current financial debt — — — (4,550) (4,550) Current financial debt — — — (136) (136) Derivative financial instruments — (1) — — (1) Financial liabilities at fair value and amortized cost — (1) (94) (4,686) (4,781) (1) Includes $11 million of Long-term convertible notes due from an associated company. (2) Recorded in Other non-current assets. (3) Recorded in Other current assets. (4) The carrying amount is a reasonable approximation of fair value, with the exception of the Series 2026, 2028, 2029, 2030, 2032, 2049 and 2052 Notes recorded in Non-current financial debt with a fair value of $4,232 million and a carrying value of $4,550 million as of June 30, 2024. The fair value of notes was determined using Level 2 inputs. The notes were valued using the quoted market price for such notes, which have low trading volumes. December 31, 2023 ($ millions) Level 1 Level 2 Level 3 Valued at amortized cost or cost (4) Total Non-current financial assets Long-term financial investments measured at FVOCI (1) — — 147 — 147 Long-term financial investments measured at FVPL — — 1 — 1 Long-term note receivable and other financial assets measured at amortized cost — — — 161 161 Long-term receivables from customers — — — 126 126 Deferred compensation assets (2) 163 — — — 163 Non-current minimum lease payments from finance lease agreements — — — 38 38 Long-term loans, VAT receivables, advances and security deposits — — — 44 44 Non-current financial assets 163 — 148 369 680 Current financial assets Money market funds 84 — — — 84 Current portion of long-term financial investments measured at FVPL (3) — — 7 — 7 Current portion of long-term receivables from customers (3) — — — 116 116 Current portion of minimum lease payments from finance lease agreements (3) — — — 27 27 VAT receivables (3) — — — 62 62 Other receivables, security deposits and current assets (3) — — — 101 101 Derivative financial instruments (3) — 2 — — 2 Current financial assets 84 2 7 306 399 Financial assets at fair value and amortized cost or cost 247 2 155 675 1,079 Financial liabilities Contingent consideration liabilities — — (90) — (90) Non-current financial debt — — — (4,676) (4,676) Current financial debt — — — (53) (53) Derivative financial instruments — (10) — — (10) Financial liabilities at fair value and amortized cost — (10) (90) (4,729) (4,829) (1) Includes $11 million of Long-term convertible notes due from an associated company. (2) Recorded in Other non-current assets. (3) Recorded in Other current assets. (4) The carrying amount is a reasonable approximation of fair value, with the exception of the Series 2026, 2028, 2029, 2030, 2032, 2049 and 2052 Notes recorded in Non-current financial debt with a fair value of $4,347 million and a carrying value of $4,566 million as of December 31, 2023. The fair value of notes was determined using Level 2 inputs. The notes were valued using the quoted market price for such notes, which have low trading volumes. Financial assets Long-term financial investments measured Financial investments ($ millions) 2024 2023 2024 2023 Balance as of January 1 147 88 8 20 Additions 90 53 — 8 Gains recognized in Consolidated Statement of Comprehensive Income 6 2 — — Gains/(losses) in Consolidated Income Statement — — 2 (4) Amortization — — (2) (1) Settlement — — (5) — Balance as of June 30 243 143 3 23
Disclosure of fair value measurement of liabilities	The below tables summarize financial assets and liabilities measured at fair value on a recurring basis or at amortized cost or cost as of June 30, 2024 and December 31, 2023. June 30, 2024 ($ millions) Level 1 Level 2 Level 3 Valued at amortized cost or cost (4) Total Non-current financial assets Long-term financial investments measured at FVOCI (1) — — 243 — 243 Long-term financial investments measured at FVPL — — 1 — 1 Long-term note receivable and other financial assets measured at amortized cost — — — 168 168 Long-term receivables from customers — — — 118 118 Deferred compensation assets (2) 172 — — — 172 Non-current minimum lease payments from finance lease agreements — — — 35 35 Long-term loans, VAT receivables, advances and security deposits — — — 43 43 Non-current financial assets 172 — 244 364 780 Current financial assets Money market funds 237 — — — 237 Current portion of long-term financial investments measured at FVPL (3) — — 2 — 2 Current portion of long-term receivables from customers (3) — — — 115 115 Current portion of minimum lease payments from finance lease agreements (3) — — — 27 27 VAT receivables (3) — — — 61 61 Other receivables, security deposits and current assets (3) — — — 98 98 Derivative financial instruments (3) — 11 — — 11 Current financial assets 237 11 2 301 551 Financial assets at fair value and amortized cost or cost 409 11 246 665 1,331 Financial liabilities Contingent consideration liabilities — — (94) — (94) Non-current financial debt — — — (4,550) (4,550) Current financial debt — — — (136) (136) Derivative financial instruments — (1) — — (1) Financial liabilities at fair value and amortized cost — (1) (94) (4,686) (4,781) (1) Includes $11 million of Long-term convertible notes due from an associated company. (2) Recorded in Other non-current assets. (3) Recorded in Other current assets. (4) The carrying amount is a reasonable approximation of fair value, with the exception of the Series 2026, 2028, 2029, 2030, 2032, 2049 and 2052 Notes recorded in Non-current financial debt with a fair value of $4,232 million and a carrying value of $4,550 million as of June 30, 2024. The fair value of notes was determined using Level 2 inputs. The notes were valued using the quoted market price for such notes, which have low trading volumes. December 31, 2023 ($ millions) Level 1 Level 2 Level 3 Valued at amortized cost or cost (4) Total Non-current financial assets Long-term financial investments measured at FVOCI (1) — — 147 — 147 Long-term financial investments measured at FVPL — — 1 — 1 Long-term note receivable and other financial assets measured at amortized cost — — — 161 161 Long-term receivables from customers — — — 126 126 Deferred compensation assets (2) 163 — — — 163 Non-current minimum lease payments from finance lease agreements — — — 38 38 Long-term loans, VAT receivables, advances and security deposits — — — 44 44 Non-current financial assets 163 — 148 369 680 Current financial assets Money market funds 84 — — — 84 Current portion of long-term financial investments measured at FVPL (3) — — 7 — 7 Current portion of long-term receivables from customers (3) — — — 116 116 Current portion of minimum lease payments from finance lease agreements (3) — — — 27 27 VAT receivables (3) — — — 62 62 Other receivables, security deposits and current assets (3) — — — 101 101 Derivative financial instruments (3) — 2 — — 2 Current financial assets 84 2 7 306 399 Financial assets at fair value and amortized cost or cost 247 2 155 675 1,079 Financial liabilities Contingent consideration liabilities — — (90) — (90) Non-current financial debt — — — (4,676) (4,676) Current financial debt — — — (53) (53) Derivative financial instruments — (10) — — (10) Financial liabilities at fair value and amortized cost — (10) (90) (4,729) (4,829) (1) Includes $11 million of Long-term convertible notes due from an associated company. (2) Recorded in Other non-current assets. (3) Recorded in Other current assets. (4) The carrying amount is a reasonable approximation of fair value, with the exception of the Series 2026, 2028, 2029, 2030, 2032, 2049 and 2052 Notes recorded in Non-current financial debt with a fair value of $4,347 million and a carrying value of $4,566 million as of December 31, 2023. The fair value of notes was determined using Level 2 inputs. The notes were valued using the quoted market price for such notes, which have low trading volumes. Financial liabilities Contingent consideration liabilities ($ millions) 2024 2023 Balance as of January 1 (90) (98) Accretion for passage of time (4) (4) Balance as of June 30 (94) (102)
Disclosure of net value of unsettled positions for derivative forward contracts and swaps	The below table summarizes the net value of unsettled positions for currency derivatives contracts including swaps, forwards and options as of June 30, 2024 and December 31, 2023. ($ millions) June 30, 2024 December 31, 2023 Unrealized gains in Other current assets 11 2 Unrealized losses in Current financial debts (1) (10) Net value of unsettled positions for derivatives contracts 10 (8)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - additional details (Tables)	6 Months Ended
	Jun. 30, 2024
Cash Flow Statement [Abstract]
Depreciation, amortization, impairments and fair value adjustments	Six months ended June 30 ($ millions) 2024 2023 Property, plant & equipment 191 182 Right-of-use assets 40 40 Intangible assets 376 377 Financial assets — 5 Other non-current assets (1) (1) Total 606 603
Change in net current assets and other operating cash flow items	Six months ended June 30 ($ millions) 2024 2023 (Increase) in inventories (71) (198) (Increase) in trade receivables (116) (138) Increase in trade payables 72 36 Net change in other operating assets (3) (44) Net change in other operating liabilities (198) (76) Total (316) (420)

Equity-based compensation (Tabl

Equity-based compensation (Tables)	6 Months Ended
Equity-based compensation (Tables)	Jun. 30, 2024
Share-Based Payment Arrangements [Abstract]
Summary of unvested share movements	The below table summarizes unvested share movements for all Alcon equity-based incentive plans for the six months ended June 30, 2024 and 2023: Six months ended June 30 (shares in millions) 2024 2023 Unvested at January 1 4.9 4.8 Granted 2.2 2.2 Vested (1.7) (1.8) Forfeited (0.1) (0.1) Unvested at June 30 5.3 5.1

Selected accounting policies (D

Selected accounting policies (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Corporate Information And Statement Of IFRS Compliance [Line Items]
Current financial debts	$ 137	$ 63
Non-current financial debts	$ 4,550	4,676
Cumulative Effect, Period of Adoption, Adjustment
Corporate Information And Statement Of IFRS Compliance [Line Items]
Current financial debts		(82)
Non-current financial debts		$ 82

Segmentation of key figures - N

Segmentation of key figures - Narrative (Details)	Jun. 30, 2024 segment
Operating Segments [Abstract]
Number of reportable segments	2

Segmentation of key figures -_2

Segmentation of key figures - Net sales by segment and Consolidated income statements (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disclosure of operating segments [line items]
Net sales to third parties	$ 2,482	$ 2,402	$ 4,926	$ 4,735
Other revenues	14	20	29	39
Net sales and other revenues	2,496	2,422	4,955	4,774
Total segment contribution	583	581	1,227	1,161
Amortization of intangible assets	(184)	(187)	(367)	(377)
Impairment charges on intangible assets	(9)	0	(9)	0
General & administration (corporate)	(73)	(74)	(148)	(142)
Transformation costs	0	(26)	0	(52)
Integration related costs	0	(8)	0	(14)
Other	1	(16)	(17)	(38)
Operating income	318	270	686	538
Interest expense	(50)	(48)	(95)	(95)
Other financial income & expense	12	(9)	24	(17)
Income before taxes	280	213	615	426
Surgical
Disclosure of operating segments [line items]
Net sales to third parties	1,423	1,382	2,761	2,686
Total segment contribution	403	407	789	788
Surgical \| Implantables
Disclosure of operating segments [line items]
Net sales to third parties	464	437	897	864
Surgical \| Consumables
Disclosure of operating segments [line items]
Net sales to third parties	736	714	1,422	1,370
Surgical \| Equipment/other
Disclosure of operating segments [line items]
Net sales to third parties	223	231	442	452
Vision Care
Disclosure of operating segments [line items]
Net sales to third parties	1,059	1,020	2,165	2,049
Total segment contribution	180	174	438	373
Vision Care \| Contact lenses
Disclosure of operating segments [line items]
Net sales to third parties	636	594	1,307	1,209
Vision Care \| Ocular health
Disclosure of operating segments [line items]
Net sales to third parties	$ 423	$ 426	$ 858	$ 840

Segmentation of key figures -_3

Segmentation of key figures - Net sales by region (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disclosure of geographical areas [line items]
Net sales to third parties	$ 2,482	$ 2,402	$ 4,926	$ 4,735
Percentage of entity's revenue	100%	100%	100%	100%
United States
Disclosure of geographical areas [line items]
Net sales to third parties	$ 1,141	$ 1,105	$ 2,290	$ 2,183
Percentage of entity's revenue	46%	46%	46%	46%
International
Disclosure of geographical areas [line items]
Net sales to third parties	$ 1,341	$ 1,297	$ 2,636	$ 2,552
Percentage of entity's revenue	54%	54%	54%	54%

Dividends and earnings per sh_2

Dividends and earnings per share (Details) shares in Millions, $ in Millions			1 Months Ended		3 Months Ended		6 Months Ended
	Feb. 27, 2024 SFr / shares	Feb. 27, 2023 SFr / shares	May 31, 2024 USD ($)	May 31, 2023 USD ($)	Jun. 30, 2024 shares	Jun. 30, 2023 shares	Jun. 30, 2024 shares	Jun. 30, 2023 shares
Earnings per share [abstract]
Dividend declared (in dollars per share) \| SFr / shares	SFr 0.24	SFr 0.21
Dividends paid \| $			$ 130	$ 116
Number of shares outstanding					494.5		494.5
Number of shares vested							1.2
Weighted average number of shares outstanding - basic (in shares)					494.5	493.2	494.1	492.8
Weighted average number of shares outstanding - diluted (in shares)					497	495.7	496.7	495.9
Potentially dilutive shares (in shares)					2.5	2.5	2.6	3.1

Intangible assets other than _2

Intangible assets other than goodwill (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disclosure of detailed information about intangible assets [abstract]
Impairment of intangibles	$ 9	$ 0	$ 9	$ 0

Non-current and current finan_3

Non-current and current financial debts - Schedule of financial debts (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Disclosure of detailed information about borrowings [line items]
Total non-current financial debts	$ 4,550	$ 4,676
Total current financial debts	137	63
Total financial debts	4,687	4,739
Local facilities (Japan), floating rate debt due 2025
Disclosure of detailed information about borrowings [line items]
Total non-current financial debts	0	110
Total current financial debts	$ 74	0
Series 2026 Notes
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate	2.75%
Total non-current financial debts	$ 498	498
Series 2028 Notes
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate	2.375%
Total non-current financial debts	$ 531	549
Series 2029 Notes
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate	3%
Total non-current financial debts	$ 995	994
Series 2030 Notes
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate	2.60%
Total non-current financial debts	$ 746	746
Series 2032 Notes
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate	5.375%
Total non-current financial debts	$ 693	693
Series 2049 Notes
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate	3.80%
Total non-current financial debts	$ 495	494
Series 2052 Notes
Disclosure of detailed information about borrowings [line items]
Borrowings, interest rate	5.75%
Total non-current financial debts	$ 592	592
Revolving facility, floating rate due 2028
Disclosure of detailed information about borrowings [line items]
Total non-current financial debts	0	0
Local facilities, all others
Disclosure of detailed information about borrowings [line items]
Total current financial debts	50	48
Other short-term financial debts, floating rate
Disclosure of detailed information about borrowings [line items]
Total current financial debts	12	5
Derivatives
Disclosure of detailed information about borrowings [line items]
Total current financial debts	$ 1	$ 10

Non-current and current finan_4

Non-current and current financial debts - Additional information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disclosure of detailed information about borrowings [line items]
Interest expense	$ 43	$ 40	$ 83	$ 81
Revolving facility, floating rate due 2028
Disclosure of detailed information about borrowings [line items]
Undrawn borrowing facilities	$ 1,320		$ 1,320

Financial instruments - Schedul

Financial instruments - Schedule of fair value of assets and liabilities (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	$ 608	$ 517
Non-current convertible note from associated company	11	11
Senior Notes Due 2026, 2028, 2029, 2030, 2032, 2049 and 2052
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, at fair value	4,232	4,347
Measured at FVPL \| Contingent consideration liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, at fair value and amortized cost	(94)	(90)
Measured at FVPL \| Derivative financial instruments
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, at fair value and amortized cost	(1)	(10)
Measured at amortized cost or cost
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, at fair value and amortized cost	(4,686)	(4,729)
Measured at amortized cost or cost \| Senior Notes Due 2026, 2028, 2029, 2030, 2032, 2049 and 2052
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, at fair value and amortized cost	(4,550)	(4,566)
Measured at amortized cost or cost \| Non-current financial debt
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, at fair value and amortized cost	(4,550)	(4,676)
Measured at amortized cost or cost \| Current financial debt
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, at fair value and amortized cost	(136)	(53)
Measured at amortized cost or cost and fair value
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, at fair value and amortized cost	(4,781)
Money market funds
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Current financial assets	237	84
Measured at FVOCI \| Long-term financial investments
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	243	147
Measured at amortized cost or cost and fair value
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	780	680
Current financial assets	551	399
Financial assets at fair value and amortized cost or cost	1,331	1,079
Financial liabilities, at fair value and amortized cost		(4,829)
Measured at FVPL \| Long-term financial investments
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	1	1
Measured at FVPL \| Deferred compensation assets
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	172	163
Measured at FVPL \| Derivative financial instruments
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Current financial assets	11	2
Measured at FVPL \| Current portion of long-term financial investments
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Current financial assets	2	7
Measured at amortized cost or cost
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	364	369
Current financial assets	301	306
Financial assets at fair value and amortized cost or cost	665	675
Measured at amortized cost or cost \| Long-term note receivable and other financial assets
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	168	161
Current financial assets	1
Financial assets at fair value and amortized cost or cost	169
Measured at amortized cost or cost \| Long-term receivables from customers
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	118	126
Current financial assets	115	116
Measured at amortized cost or cost \| Minimum lease payments from finance lease agreements
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	35	38
Current financial assets	27	27
Measured at amortized cost or cost \| Long-term loans, VAT receivables, advances and security deposits
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	43	44
Measured at amortized cost or cost \| VAT receivables
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Current financial assets	61	62
Measured at amortized cost or cost \| Other receivables, security deposits and current assets
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Current financial assets	98	101
Level 3 \| Contingent consideration liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, at fair value and amortized cost	(94)	(90)	$ (102)	$ (98)
Recurring fair value measurement \| Level 1
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	172	163
Current financial assets	237	84
Financial assets at fair value and amortized cost or cost	409	247
Financial liabilities, at fair value and amortized cost	0	0
Recurring fair value measurement \| Level 1 \| Measured at FVPL \| Contingent consideration liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, at fair value and amortized cost	0	0
Recurring fair value measurement \| Level 1 \| Measured at FVPL \| Derivative financial instruments
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, at fair value and amortized cost	0	0
Recurring fair value measurement \| Level 1 \| Measured at amortized cost or cost \| Non-current financial debt
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, at fair value and amortized cost	0	0
Recurring fair value measurement \| Level 1 \| Measured at amortized cost or cost \| Current financial debt
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, at fair value and amortized cost	0	0
Recurring fair value measurement \| Level 1 \| Money market funds
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Current financial assets	237	84
Recurring fair value measurement \| Level 1 \| Measured at FVOCI \| Long-term financial investments
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	0	0
Recurring fair value measurement \| Level 1 \| Measured at FVPL \| Long-term financial investments
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	0	0
Recurring fair value measurement \| Level 1 \| Measured at FVPL \| Deferred compensation assets
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	172	163
Recurring fair value measurement \| Level 1 \| Measured at FVPL \| Derivative financial instruments
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Current financial assets	0	0
Recurring fair value measurement \| Level 1 \| Measured at FVPL \| Current portion of long-term financial investments
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Current financial assets	0	0
Recurring fair value measurement \| Level 1 \| Measured at amortized cost or cost \| Long-term note receivable and other financial assets
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	0	0
Recurring fair value measurement \| Level 1 \| Measured at amortized cost or cost \| Long-term receivables from customers
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	0	0
Current financial assets	0	0
Recurring fair value measurement \| Level 1 \| Measured at amortized cost or cost \| Minimum lease payments from finance lease agreements
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	0	0
Current financial assets	0	0
Recurring fair value measurement \| Level 1 \| Measured at amortized cost or cost \| Long-term loans, VAT receivables, advances and security deposits
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	0	0
Recurring fair value measurement \| Level 1 \| Measured at amortized cost or cost \| VAT receivables
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Current financial assets	0	0
Recurring fair value measurement \| Level 1 \| Measured at amortized cost or cost \| Other receivables, security deposits and current assets
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Current financial assets	0	0
Recurring fair value measurement \| Level 2
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	0	0
Current financial assets	11	2
Financial assets at fair value and amortized cost or cost	11	2
Financial liabilities, at fair value and amortized cost	(1)	(10)
Recurring fair value measurement \| Level 2 \| Measured at FVPL \| Contingent consideration liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, at fair value and amortized cost	0	0
Recurring fair value measurement \| Level 2 \| Measured at FVPL \| Derivative financial instruments
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, at fair value and amortized cost	(1)	(10)
Recurring fair value measurement \| Level 2 \| Measured at amortized cost or cost \| Non-current financial debt
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, at fair value and amortized cost	0	0
Recurring fair value measurement \| Level 2 \| Measured at amortized cost or cost \| Current financial debt
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, at fair value and amortized cost	0	0
Recurring fair value measurement \| Level 2 \| Money market funds
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Current financial assets	0	0
Recurring fair value measurement \| Level 2 \| Measured at FVOCI \| Long-term financial investments
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	0	0
Recurring fair value measurement \| Level 2 \| Measured at FVPL \| Long-term financial investments
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	0	0
Recurring fair value measurement \| Level 2 \| Measured at FVPL \| Deferred compensation assets
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	0	0
Recurring fair value measurement \| Level 2 \| Measured at FVPL \| Derivative financial instruments
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Current financial assets	11	2
Recurring fair value measurement \| Level 2 \| Measured at FVPL \| Current portion of long-term financial investments
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Current financial assets	0	0
Recurring fair value measurement \| Level 2 \| Measured at amortized cost or cost \| Long-term note receivable and other financial assets
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	0	0
Recurring fair value measurement \| Level 2 \| Measured at amortized cost or cost \| Long-term receivables from customers
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	0	0
Current financial assets	0	0
Recurring fair value measurement \| Level 2 \| Measured at amortized cost or cost \| Minimum lease payments from finance lease agreements
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	0	0
Current financial assets	0	0
Recurring fair value measurement \| Level 2 \| Measured at amortized cost or cost \| Long-term loans, VAT receivables, advances and security deposits
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	0	0
Recurring fair value measurement \| Level 2 \| Measured at amortized cost or cost \| VAT receivables
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Current financial assets	0	0
Recurring fair value measurement \| Level 2 \| Measured at amortized cost or cost \| Other receivables, security deposits and current assets
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Current financial assets	0	0
Recurring fair value measurement \| Level 3
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	244	148
Current financial assets	2	7
Financial assets at fair value and amortized cost or cost	246	155
Financial liabilities, at fair value and amortized cost	(94)	(90)
Recurring fair value measurement \| Level 3 \| Measured at FVPL \| Contingent consideration liabilities
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, at fair value and amortized cost	(94)	(90)
Recurring fair value measurement \| Level 3 \| Measured at FVPL \| Derivative financial instruments
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, at fair value and amortized cost	0	0
Recurring fair value measurement \| Level 3 \| Measured at amortized cost or cost \| Non-current financial debt
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, at fair value and amortized cost	0	0
Recurring fair value measurement \| Level 3 \| Measured at amortized cost or cost \| Current financial debt
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Financial liabilities, at fair value and amortized cost	0	0
Recurring fair value measurement \| Level 3 \| Money market funds
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Current financial assets	0	0
Recurring fair value measurement \| Level 3 \| Measured at FVOCI \| Long-term financial investments
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	243	147
Recurring fair value measurement \| Level 3 \| Measured at FVPL \| Long-term financial investments
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	1	1
Recurring fair value measurement \| Level 3 \| Measured at FVPL \| Deferred compensation assets
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	0	0
Recurring fair value measurement \| Level 3 \| Measured at FVPL \| Derivative financial instruments
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Current financial assets	0	0
Recurring fair value measurement \| Level 3 \| Measured at FVPL \| Current portion of long-term financial investments
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Current financial assets	2	7
Recurring fair value measurement \| Level 3 \| Measured at amortized cost or cost \| Long-term note receivable and other financial assets
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	0	0
Recurring fair value measurement \| Level 3 \| Measured at amortized cost or cost \| Long-term receivables from customers
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	0	0
Current financial assets	0	0
Recurring fair value measurement \| Level 3 \| Measured at amortized cost or cost \| Minimum lease payments from finance lease agreements
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	0	0
Current financial assets	0	0
Recurring fair value measurement \| Level 3 \| Measured at amortized cost or cost \| Long-term loans, VAT receivables, advances and security deposits
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Non-current financial assets	0	0
Recurring fair value measurement \| Level 3 \| Measured at amortized cost or cost \| VAT receivables
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Current financial assets	0	0
Recurring fair value measurement \| Level 3 \| Measured at amortized cost or cost \| Other receivables, security deposits and current assets
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Line Items]
Current financial assets	$ 0	$ 0

Financial instruments - Activit

Financial instruments - Activity in level 3 financial assets (Details) - Level 3 - Financial investments - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Measured at FVOCI
Changes in fair value measurement, assets [abstract]
Balance as of January 1	$ 147	$ 88
Additions	90	53
Gains recognized in Consolidated Statement of Comprehensive Income	6	2
Gains/(losses) in Consolidated Income Statement	0	0
Amortization	0	0
Settlement	0	0
Balance as of June 30	243	143
Measured at FVPL
Changes in fair value measurement, assets [abstract]
Balance as of January 1	8	20
Additions	0	8
Gains recognized in Consolidated Statement of Comprehensive Income	0	0
Gains/(losses) in Consolidated Income Statement	2	(4)
Amortization	(2)	(1)
Settlement	(5)	0
Balance as of June 30	$ 3	$ 23

Financial instruments - Activ_2

Financial instruments - Activity in level 3 financial liabilities (Details) - Level 3 - Contingent consideration liabilities - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Changes in fair value measurement, liabilities [abstract]
Balance as of January 1	$ (90)	$ (98)
Accretion for passage of time	(4)	(4)
Balance as of June 30	$ (94)	$ (102)

Financial instruments - Additio

Financial instruments - Additional information (Details) $ in Millions	6 Months Ended
	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
Disclosure of detailed information about borrowings [line items]
Contingent amount	$ 395
Non-current financial assets	608	$ 517
Collateral amount	$ 320
Collateral decrease percentage	15%
Measured at amortized cost or cost
Disclosure of detailed information about borrowings [line items]
Financial assets	$ 665	675
Non-current financial assets	364	369
Current financial assets	301	306
Measured at amortized cost or cost \| Long-term note receivable and other financial assets
Disclosure of detailed information about borrowings [line items]
Financial assets	169
Non-current financial assets	168	$ 161
Current financial assets	$ 1
Minimum
Disclosure of detailed information about borrowings [line items]
Probability of success, contingent consideration	0.03
Maximum
Disclosure of detailed information about borrowings [line items]
Probability of success, contingent consideration	0.55

Financial instruments - Disclos

Financial instruments - Disclosure of net value of unsettled positions for derivative forward contracts and swaps (Details) - USD ($) $ in Millions	Jun. 30, 2024	Dec. 31, 2023
Financial Instruments [Abstract]
Unrealized gains in Other current assets	$ 11	$ 2
Unrealized losses in Current financial debts	(1)	(10)
Net value of unsettled positions for derivatives contracts	$ 10	$ (8)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - additional details - Depreciation, amortization, impairments and fair value adjustments (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Disclosure of detailed information about property, plant and equipment [line items]
Total	$ 606	$ 603
Property, plant & equipment
Disclosure of detailed information about property, plant and equipment [line items]
Total	191	182
Right-of-use assets
Disclosure of detailed information about property, plant and equipment [line items]
Total	40	40
Intangible assets
Disclosure of detailed information about property, plant and equipment [line items]
Total	376	377
Financial assets
Disclosure of detailed information about property, plant and equipment [line items]
Total	0	5
Other non-current assets
Disclosure of detailed information about property, plant and equipment [line items]
Total	$ (1)	$ (1)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - additional details - Change in net current assets and other operating cash flow items (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash Flow Statement [Abstract]
(Increase) in inventories	$ (71)	$ (198)
(Increase) in trade receivables	(116)	(138)
Increase in trade payables	72	36
Net change in other operating assets	(3)	(44)
Net change in other operating liabilities	(198)	(76)
Total	$ (316)	$ (420)

Equity-based compensation (Deta

Equity-based compensation (Details) - shares shares in Millions	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-Based Payment Arrangements [Abstract]
Unvested (in shares)	4.9	4.8
Granted (in shares)	2.2	2.2
Vested (in shares)	(1.7)	(1.8)
Forfeited (in shares)	(0.1)	(0.1)
Unvested (in shares)	5.3	5.1

Related parties transactions (D

Related parties transactions (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Related Party [Abstract]
Proportion of ownership interest in associate	8.50%
Investments in associates accounted for using equity method	$ 10	$ 10
Non-current convertible note from associated company	$ 11	$ 11

Subsequent events (Details)

Subsequent events (Details)	Aug. 12, 2024
Potential ordinary share transactions
Disclosure of non-adjusting events after reporting period [line items]
Divestiture of licensing rights, consideration to receive, percentage of ordinary shares	16.70%